Clarithromycin
NDC 63304-725
Product Information
Clarithromycin is a ANDA-approved product labeled by Ranbaxy Pharmaceuticals Inc.. Clarithromycin is used to treat a wide variety of bacterial infections. It is supplied as a yellow product. This product entry covers the primary NDC 63304-725 and 5 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
RX;725
Code Structure Chart
Product Details
What is NDC 63304-725?
What are the uses of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- CLARITHROMYCIN (UNII: H1250JIK0A)
- CLARITHROMYCIN (UNII: H1250JIK0A) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- COLLOIDAL SILICON DIOXIDE (UNII: ETJ7Z6XBU4)
- CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)
- D&C YELLOW NO. 10 (UNII: 35SW5USQ3G)
- HYDROXYPROPYL CELLULOSE (UNII: RFW2ET671P)
- POVIDONE (UNII: FZ989GH94E)
- HYPROMELLOSES (UNII: 3NXW29V3WO)
- MAGNESIUM STEARATE (UNII: 70097M6I30)
- CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)
- PROPYLENE GLYCOL (UNII: 6DC9Q167V3)
- SHELLAC (UNII: 46N107B71O)
- STEARIC ACID (UNII: 4ELV7Z65AP)
- TALC (UNII: 7SEV7J4R1U)
- TITANIUM DIOXIDE (UNII: 15FIX9V2JP)
- FERROSOFERRIC OXIDE (UNII: XM0M87F357)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 197516 - clarithromycin 250 MG Oral Tablet
- RxCUI: 197517 - clarithromycin 500 MG Oral Tablet
- RxCUI: 240741 - clarithromycin 125 MG in 5 mL Oral Suspension
- RxCUI: 240741 - clarithromycin 25 MG/ML Oral Suspension
- RxCUI: 240741 - clarithromycin 125 MG per 5 ML Oral Suspension
* Please review the full disclaimer at the bottom of this page.